Alto Neuroscience
Alto Neuroscience, a US-based clinical-stage biopharma, develops precision medicines using AI-driven biomarkers.
Founded
2019Alto Neuroscience, a US-based clinical-stage biopharma, develops precision medicines using AI-driven biomarkers.
Founded in Los Altos, United States, Alto Neuroscience is a clinical-stage biopharmaceutical company with a core mission to revolutionize psychiatric drug development through precision medicine. Utilizing an AI-driven biomarker platform, the company aims to match the right patient with the right drug, thereby enhancing treatment efficacy and patient outcomes. Their innovative approach focuses on creating tailored medications for various psychiatric conditions, addressing a critical need in mental health care.
Notable figures affiliated with Alto Neuroscience include leading experts in neuroscience and AI technology. The company has garnered significant investment from prominent venture capital firms, underscoring confidence in its groundbreaking approach. Key achievements include advancing multiple drug candidates through clinical trials and publishing influential research in top scientific journals. Alto Neuroscience's impact lies in its potential to transform mental health treatment by providing personalized therapeutic options, setting a new standard in psychiatric care.
Companies similar to Alto Neuroscience include Gilgamesh Pharmaceuticals, Tetricus Labs, NeuroX1 and Reservoir Neuroscience.
Alto Neuroscience was founded in 2019.
Alto Neuroscience's headquarters is located in Los Altos, CA, US.
Alto Neuroscience's most recent funding round was for $45M (USD) in November 2023.
As of Nov 21, 2023, Alto Neuroscience has raised a total of $239.3M (USD).
Alto Neuroscience has 72 employees as of Feb 5, 2024.
NeuroX1
neurox1.com
